Publications

Pour rechercher une publication scientifique, insérez vos mots-clés en anglais.
O'Brien DP Sauvageot D Olson D Schaeffer M Humblet P Pudjades M Ellman T Zachariah R Szumilin E Arnould L Read T
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007 May 01; 44(9); 1245-8. doi: 10.1086/513433. Epub 2007 03 28

Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.

Abstract

BACKGROUND: Relapses originating from hypnozoites are characteristic of Plasmodium vivax infections. Thus, reappearance of parasitemia after treatment can result from relapse, recrudescence, or reinfection.

Imwong M Snounou G Pukrittayakamee S Tanomsing N Kim JR Nandy A Guthmann JP Nosten F Carlton J Looareesuwan S Nair S Sudimack D Day NP Anderson TJ White NJ
The Journal of infectious diseases 2007 Apr 01; 195(7); 927-33. doi: 10.1086/512241. Epub 2007 02 26

Could nutritional rehabilitation at home complement or replace centre-based therapeutic feeding programmes for severe malnutrition?

Abstract

To measure the success rate of three different strategies used in Médecins Sans Frontières large-scale therapeutic nutritional rehabilitation programme in Niger, we analysed three cohorts of severely malnourished patients in terms of daily weight gain,

Gaboulaud V Dan-Bouzoua N Brasher C Fedida G Gergonne B Brown V
Journal of tropical pediatrics 2007 Feb ; 53(1); 49-51. doi: 10.1093/tropej/fml052. Epub 2006 10 09

Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment.

Abstract

Polymerase chain reaction (PCR) genotyping of malaria parasites in drug efficacy trials helps differentiate reinfections from recrudescences.

Mugittu K Priotto G Guthmann JP Kiguli J Adjuik M Snounou G Beck HP Mshinda H Olliaro PL Taylor WR
Tropical medicine & international health : TM & IH 2007 Feb ; 12(2); 219-23. doi: 10.1111/j.1365-3156.2007.01813.x. Epub 2007 03 15

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.

Abstract

OBJECTIVE: To facilitate the choice of the best visceral leishmaniasis (VL) treatment strategy for first-line health services in (VL)-endemic areas, we compared in a formal decision analysis the cost and the cost-effectiveness of the d

Vanlerberghe V Diap G Guerin PJ Meheus F Gerstl S Van der Stuyft P Boelaert M
Tropical medicine & international health : TM & IH 2007 Feb ; 12(2); 274-83. doi: 10.1111/j.1365-3156.2006.01782.x. Epub 2007 03 15

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.

Abstract

BACKGROUND: HAART efficacy was evaluated in a real-life setting in Phnom Penh (Médecins Sans Frontières programme) among severely immuno-compromised patients.

Madec Y Laureillard D Pinoges L Fernandez M Prak N Ngeth C Moeung S Song S Balkan S Ferradini L Quillet C Fontanet A
AIDS (London, England) 2007 Jan 30; 21(3); 351-9. doi: 10.1097/QAD.0b013e328012c54f. Epub 2007 05 07

Unacceptably high mortality related to measles epidemics in Niger, Nigeria, and Chad.

Abstract

BACKGROUND: Despite the comprehensive World Health Organization (WHO)/United Nations Children's Fund (UNICEF) measles mortality-reduction strategy and the Measles Initiative, a partnership of international organizations supporting meas

Grais RF Dubray C Gerstl S Guthmann JP Djibo A Nargaye KD Coker J Alberti KP Cochet A Ihekweazu C Nathan N Payne L Porten K Sauvageot D Schimmer B Fermon F Burny ME Hersh BS Guerin PJ
PLoS medicine 2007 Jan ; 4(1); e16. doi: 10.1371/journal.pmed.0040016. Epub 2007 08 24

Death rates from malaria epidemics, Burundi and Ethiopia.

Abstract

Death rates exceeded emergency thresholds at 4 sites during epidemics of Plasmodium falciparum malaria in Burundi (2000-2001) and in Ethiopia (2003-2004).

Guthmann JP Bonnet M Ahoua L Dantoine F Balkan S van Herp M Tamrat A Legros D Brown V Checchi F
Emerging infectious diseases 2007 Jan ; 13(1); 140-3. doi: 10.3201/eid1301.060546. Epub 2007 04 18

Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda.

Abstract

OBJECTIVES: Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense.

Priotto G Fogg C Balasegaram M Erphas O Louga A Checchi F Ghabri S Piola P
PLoS clinical trials 2006 Dec 08; 1(8); e39. doi: 10.1371/journal.pctr.0010039. Epub 2006 12 08